The Next Decade To See Escalation Of The Uveitis Market, Making It Reach US$ 840 Million

The Uveitis Market will witness a CAGR of 6.5%, reaching US$ 840 Million between 2024. With medical IoT implying the use of wearable monitors, devices, and various integrated applications regarding healthcare needs, the healthcare vertical is bound to scale new-fangled heights in the upcoming period. This is what the healthcare vertical would all be in the next 10 years.

The US$ 497 Mn uveitis treatment market is likely to expand at a stable CAGR of 6.5% over the next eight years. In 2017, the market is expected to witness nearly 6.7% Y-o-Y growth over 2016. During 2016-2024, Persistence Market Research predicts a positive growth outlook for the global uveitis treatment market, influenced by several growth drivers, restraints, trends, and opportunities.

Want Insights To Uveitis Market? Ask For Sample! https://www.persistencemarketresearch.co/samples/3596

In its recently published report titled “Uveitis Treatment Market: Industry Analysis and Forecast, 2016–2024,” the company provides in-depth analysis of the market growth prospects for the eight-year assessment period, backing it up with historic and current market data.

Company Profiles

Allergan, Inc.,
Bausch & Lomb Incorporated.
Novartis AG (Alcon Laboratories Inc.)
AbbVie Inc.
Santen Pharmaceutical Co., Ltd
Eyegate Pharmaceuticals, Inc.
Alimera Sciences, Inc.
pSivida Corp.

Planning To Conclude Your Strategy On A Decisive Note In The Uveitis Market? Glance Through The “Methodology” Implied! https://www.persistencemarketresearch.co/methodology/3596

Persistence Market Research identified a few important drivers and trends that will continue to present attractive growth opportunities during 2016-2024.

While surge in autoimmune disorders is identified to primarily generate the demand for uveitis, the market has been witnessing strong emergence of immunosuppressive therapies to treat uveitis since the past few years, which is expected to create a new set of opportunities for leading players in near future.

“Some of the leading companies in the uveitis treatment marketplace have been investing in new, improved product launches since the past decade. While a significant number of uveitis drugs are already in the pipeline, increasing in-licensing approvals for new market entrants will boost the scope of treatment against uveitis, ultimately creating new lucrative opportunities,” states Persistence Market Research.

As corticosteroid mono-therapy is no more considered the first line treatment for uveitis, the market has been witnessing introduction of various modified corticosteroid medication and drug delivery methods since the recent past.
Major players in the segment are working to add novel drugs to their product portfolio.
R&D in topical agents segment will also benefit the market growth in near future.

How About Knowing The Product/Technology Driving The Uveitis Market Before Investing Therein? Click The “Purchase Now” Button Of Our Uveitis Market Report! https://www.persistencemarketresearch.com/checkout/3596

Segmentation by treatment type:

Corticosteroids
Immunosuppressants
Monoclonal antibodies
Cycloplegic agents
Antibodies
Antivirals
Antifungals
Analgesics

Corticosteroids will remain the largest segment, followed by antibiotics and monoclonal antibodies. While the corticosteroids segment is foreseen to account for a dominant market share of over 21% in 2024, the antibiotics segment is expected to witness the fastest growth at a CAGR of 8% – reaching beyond US$ 146 Mn over 2016-2024. The monoclonal antibodies segment will also exhibit healthy growth at a CAGR of 7%, reaching revenues worth US$ 142.7 Mn by the end of 2024.

Segmentation by disease type:

Anterior uveitis
Posterior uveitis
Intermediate uveitis
Panuveitis

The anterior uveitis segment will continue to dominate. Through 2024, this segment will capture around 60% value share, representing a value of over US$ 500 Mn. Posterior uveitis is also estimated for a considerable market value share of over 23% in 2024. Attributed to increased prevalence of TB in intermediate uveitis, the intermediate uveitis will possibly be the second fastest growing segment over the forecast period.

Segmentation by cause:

Infectious
Non-infectious

On the basis of cause, infectious uveitis will remain the larger segment with over 87% share by 2024 end but non-infectious uveitis is predicted to witness a higher CAGR of 7.4% during the eight-year period.

Segmentation by distribution channel:

Hospital pharmacies
Retail pharmacies
Online pharmacies
Drug stores

By distribution channel, hospital pharmacies segment will account for over 46% revenue share in 2024, whereas retail pharmacies segment is likely to capture around 30% share. Online pharmacies and drug stores segments will also witness healthy growth at over 6% CAGR during the aforementioned period.

Segmentation by region:

The report provides regional analysis that examines the global market classifying it into five key regions.

North America
Latin America
Europe
Asia Pacific (APAC)
Middle East and Africa (MEA)

North America, the largest and fastest growing regional market for uveitis treatment globally, will retain its dominant position over the assessed period. With over 34% market value share in 2024, this regional will possibly account for around US$ 290 Mn. Europe will remain the second key market with nearly 27% share by the end of forecast period, followed by Asia Pacific.

Access Related Reports-

Molecular Grade Plates Market: https://www.persistencemarketresearch.com/market-research/molecular-grade-plates-market.asp

Asian Breast Implants Market: https://www.persistencemarketresearch.com/market-research/asian-breast-implants-market.asp

Bone Marrow Transplantation Market: https://www.persistencemarketresearch.com/market-research/bone-marrow-transplantation-market.asp

Humanized Liver Mice Model Market: https://www.persistencemarketresearch.com/market-research/humanized-liver-mice-model-market.asp

Contact us:

Persistence Market Research
Address – 305 Broadway, 7th FloorNew York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com

About Us :-

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.

This release was published on openPR.